Beschreibung
Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product.
Am besten für
Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer und Hospital Administered oncology